Dalton Pharma Services
Cardiol has established an exclusive manufacturing arrangement with Dalton Pharma Services (Dalton) for supplying pharmaceutical cannabidiol at >99% purity for Cardiol’s research programs.
Located in Toronto, Canada, Dalton is a Health Canada approved, FDA registered, cGMP manufacturer of over 200 APIs, including pharmaceutical cannabinoids, with manufacturing capability scalable to support all stages of the regulatory process (Phase I, II, III and commercial). In 2016 and 2017, Dalton Pharma Services received the Leadership Award for Contract Manufacturing Organizations (CMO) in the following categories: Quality, Capabilities, Expertise, Compatibility, and Development.
In collaboration with Dalton, Cardiol is developing unique manufacturing expertise in the production of pure pharmaceutical cannabinoids in support of its nanotherapeutics program in heart failure. With de-scheduling of cannabinoids from Canada’s Controlled Drugs and Substances Act expected in the second half of 2018, Cardiol believes there is a significant opportunity to exploit this manufacturing expertise to develop and commercialize pharmaceutical cannabinoid products.